Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 6 (2009), Issue 9 (September)

1. The Center for Prostate Disease Research (CPDR): a multidisciplinary approach to translational research.
   Urol Oncol, 27(5): 562-9. [Abstract] [Full-text]
2. Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
   J Med Chem, 52(15): 4951-4. [Abstract] [Full-text]
3. Isoflavone supplements stimulated the production of serum equol and decreased the serum dihydrotestosterone levels in healthy male volunteers.
   Prostate Cancer Prostatic Dis, 12(3): 247-52. [Abstract] [Full-text]
4. Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer.
   Prostate Cancer Prostatic Dis, 12(3): 241-6. [Abstract] [Full-text]
5. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth.
   Prostate, 69(13): 1460-9. [Abstract] [Full-text]
6. Cell cycle regulator cdk2ap1 inhibits prostate cancer cell growth and modifies androgen-responsive pathway function.
   Prostate, 69(14): 1586-97. [Abstract] [Full-text]
7. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
   Prostate, 69(14): 1579-85. [Abstract] [Full-text]
8. Estimation of absolute risk for prostate cancer using genetic markers and family history.
   Prostate, 69(14): 1565-72. [Abstract] [Full-text]
9. Modeling the effects of obesity and weight gain on PSA velocity.
   Prostate, 69(14): 1573-8. [Abstract] [Full-text]
10. Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of European ancestry.
    Prostate, 69(14): 1548-56. [Abstract] [Full-text]
11. Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro.
    Prostate, 69(14): 1529-37. [Abstract] [Full-text]
12. A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies.
    Prostate, 69(14): 1507-20. [Abstract] [Full-text]
13. Signal transduction responses to lysophosphatidic acid and sphingosine 1-phosphate in human prostate cancer cells.
    Prostate, 69(14): 1493-506. [Abstract] [Full-text]
14. A [3]ferrocenophane polyphenol showing a remarkable antiproliferative activity on breast and prostate cancer cell lines.
    J Med Chem, 52(15): 4964-7. [Abstract] [Full-text]
15. Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells.
    Prostate, 69(14): 1481-92. [Abstract] [Full-text]
16. The alchemy of jargon: Etymologies of urologic neologisms. Number 5: oncology and its vocabulary.
    Prostate, 69(13): 1369-71. [Abstract] [Full-text]
17. Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate.
    Prostate, 69(13): 1378-86. [Abstract] [Full-text]
18. Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer.
    Prostate, 69(13): 1387-97. [Abstract] [Full-text]
19. Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs.
    Prostate, 69(13): 1448-59. [Abstract] [Full-text]
20. C/EBPbeta regulates metastatic gene expression and confers TNF-alpha resistance to prostate cancer cells.
    Prostate, 69(13): 1435-47. [Abstract] [Full-text]
21. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
    Prostate, 69(13): 1422-34. [Abstract] [Full-text]
22. Physical activity reduces prostate carcinogenesis in a transgenic model.
    Prostate, 69(13): 1372-7. [Abstract] [Full-text]
23. The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma.
    Prostate, 69(13): 1398-403. [Abstract] [Full-text]
24. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.
    Mod Pathol, 22(9): 1176-85. [Abstract] [Full-text]
25. Evidence for field cancerization of the prostate.
    Prostate, 69(13): 1470-9. [Abstract] [Full-text]
26. Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?
    Eur J Cancer, 45(14): 2569-73. [Abstract] [Full-text]
27. Robotic-assisted laparoscopic and radical retropubic prostatectomy generate similar positive margin rates in low and intermediate risk patients.
    Urol Oncol, 27(5): 529-33. [Abstract] [Full-text]
28. Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer.
    Urol Oncol, 27(5): 539-47. [Abstract] [Full-text]
29. A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or "insignificant".
    Urol Oncol, 27(5): 509-13. [Abstract] [Full-text]
30. Prostate carcinoma spatial distribution patterns in Chinese men investigated with systematic transperineal ultrasound guided 11-region biopsy.
    Urol Oncol, 27(5): 520-4. [Abstract] [Full-text]
31. Prostate tumor alignment and continuous, real-time adaptive radiation therapy using electromagnetic fiducials: clinical and cost-utility analyses.
    Urol Oncol, 27(5): 473-82. [Abstract] [Full-text]
32. Genetic profile identification in clinically localized prostate carcinoma.
    Urol Oncol, 27(5): 502-8. [Abstract] [Full-text]
33. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy.
    Phys Med Biol, 54(18): 5595-611. [Abstract] [Full-text]
34. The role of transforming growth factor-beta-mediated tumor-stroma interactions in prostate cancer progression: an integrative approach.
    Cancer Res, 69(17): 7111-20. [Abstract] [Full-text]
35. Dietary feeding of dibenzoylmethane inhibits prostate cancer in transgenic adenocarcinoma of the mouse prostate model.
    Cancer Res, 69(17): 7096-102. [Abstract] [Full-text]
36. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
    Cancer Res, 69(17): 6932-40. [Abstract] [Full-text]
37. Contrast-enhanced radiotherapy: feasibility and characteristics of the physical absorbed dose distribution for deep-seated tumors.
    Phys Med Biol, 54(18): 5411-25. [Abstract] [Full-text]
38. Public knowledge of benefits of breast and prostate cancer screening in Europe.
    J Natl Cancer Inst, 101(17): 1216-20. [Abstract] [Full-text]
39. Microfabricated electrospun collagen membranes for 3-D cancer models and drug screening applications.
    Biomacromolecules, 10(8): 2019-32. [Abstract] [Full-text]
40. In vivo lactate signal enhancement using binomial spectral-selective pulses in selective MQ coherence (SS-SelMQC) spectroscopy.
    Magn Reson Med, 62(3): 591-8. [Abstract] [Full-text]
41. Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer.
    Int J Radiat Biol, 85(9): 805-13. [Abstract] [Full-text]
42. Dynamic MRI and CAD vs. choline MRS: where is the detection level for a lesion characterisation in prostate cancer?
    Int J Radiat Biol, 85(9): 814-24. [Abstract] [Full-text]
43. A stochastic model for identifying differential gene pair co-expression patterns in prostate cancer progression.
    BMC Genomics, 10: 340. [Abstract] [Full-text]
44. Dietary glucosinolate intake and risk of prostate cancer in the EPIC-Heidelberg cohort study.
    Int J Cancer, 125(9): 2179-86. [Abstract] [Full-text]
45. Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells.
    Int J Cancer, 125(9): 2004-13. [Abstract] [Full-text]
46. A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy.
    J Clin Anesth, 21(5): 322-8. [Abstract] [Full-text]
47. Phytoestrogen modulation of bone-related cytokines and its impact on cell viability in human prostate cancer cells.
    Life Sci, 85(11): 421-30. [Abstract] [Full-text]
48. miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer.
    J Biol Chem, 284(37): 24696-704. [Abstract] [Full-text]
49. Hypoxia and the metabolic phenotype of prostate cancer cells.
    Biochim Biophys Acta, 1787(12): 1433-43. [Abstract] [Full-text]
50. External radiotherapy for prostate cancer with or without androgen deprivation: Geneva, 1991 to 2004.
    Swiss Med Wkly, 139(35): 511-7. [Abstract] [Full-text]
51. Image-guided radiotherapy in near real time with intensity-modulated radiotherapy megavoltage treatment beam imaging.
    Int J Radiat Oncol Biol Phys, 75(2): 603-10. [Abstract] [Full-text]
52. Physiologic reactions after proton beam therapy in patients with prostate cancer: significance of urinary autoactivation.
    Int J Radiat Oncol Biol Phys, 75(2): 580-6. [Abstract] [Full-text]
53. Combination treatment of hydrogen peroxide and X-rays induces apoptosis in human prostate cancer PC-3 cells.
    Int J Radiat Oncol Biol Phys, 75(2): 449-54. [Abstract] [Full-text]
54. Lupeol triterpene, a novel diet-based microtubule targeting agent: disrupts survivin/cFLIP activation in prostate cancer cells.
    Biochem Biophys Res Commun, 388(3): 576-82. [Abstract] [Full-text]
55. Correlation between pre- and postimplant dosimetry for iodine-125 seed implants for localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 75(2): 626-30. [Abstract] [Full-text]
56. Genistein synergizes with RNA interference inhibiting survivin for inducing DU-145 of prostate cancer cells to apoptosis.
    Cancer Lett, 284(2): 189-97. [Abstract] [Full-text]
57. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
    Int J Radiat Oncol Biol Phys, 75(2): 413-20. [Abstract] [Full-text]
58. Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins.
    Int J Radiat Oncol Biol Phys, 75(2): 407-12. [Abstract] [Full-text]
59. Prostate cancer: a newly discovered route for testosterone to reach the prostate : Treatment by super-selective intraprostatic androgen deprivation.
    Andrologia, 41(5): 305-15. [Abstract] [Full-text]
60. Outcomes of locally advanced (T3 or greater) prostate cancer in men undergoing robot-assisted laparoscopic prostatectomy.
    J Endourol, 23(9): 1519-22. [Abstract] [Full-text]
61. Increased expression of class III beta-tubulin in castration-resistant human prostate cancer.
    Br J Cancer, 101(6): 951-6. [Abstract] [Full-text]
62. Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2.
    Br J Cancer, 101(6): 940-50. [Abstract] [Full-text]
63. Prostate cancer as a first and second cancer: effect of family history.
    Br J Cancer, 101(6): 935-9. [Abstract] [Full-text]
64. Intraoperative photodynamic evaluation of surgical margins during endoscopic extraperitoneal radical prostatectomy with the use of 5-aminolevulinic acid.
    J Endourol, 23(9): 1387-94. [Abstract] [Full-text]
65. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy.
    J Clin Oncol, 27(26): 4306-13. [Abstract] [Full-text]
66. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management.
    J Clin Oncol, 27(26): 4321-6. [Abstract] [Full-text]
67. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.
    J Clin Oncol, 27(26): 4300-5. [Abstract] [Full-text]
68. Robot-assisted radical prostatectomy: current evaluation of surgical margins in clinically low-, intermediate-, and high-risk prostate cancer.
    J Endourol, 23(9): 1461-5. [Abstract] [Full-text]
69. Influence of NCI cancer center attendance on mortality in lung, breast, colorectal, and prostate cancer patients.
    Med Care Res Rev, 66(5): 542-60. [Abstract] [Full-text]
70. The chemopreventive bioflavonoid apigenin inhibits prostate cancer cell motility through the focal adhesion kinase/Src signaling mechanism.
    Cancer Prev Res (Phila Pa), 2(9): 830-41. [Abstract] [Full-text]
71. Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness.
    J Urol, 182(4): 1621-7. [Abstract] [Full-text]
72. Electrical properties of prostatic tissues: I. Single frequency admittivity properties.
    J Urol, 182(4): 1600-7. [Abstract] [Full-text]
73. Electrical properties of prostatic tissues: II. Spectral admittivity properties.
    J Urol, 182(4): 1608-13. [Abstract] [Full-text]
74. Semaphorin 3B and 3F single nucleotide polymorphisms are associated with prostate cancer risk and poor prognosis.
    J Urol, 182(4): 1614-20. [Abstract] [Full-text]
75. Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen.
    J Urol, 182(4): 1342-9. [Abstract] [Full-text]
76. Hyaluronic acid and HYAL-1 in prostate biopsy specimens: predictors of biochemical recurrence.
    J Urol, 182(4): 1350-6. [Abstract] [Full-text]
77. Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy.
    J Urol, 182(4): 1378-84. [Abstract] [Full-text]
78. Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system.
    J Urol, 182(4): 1364-70. [Abstract] [Full-text]
79. Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy.
    J Urol, 182(4): 1357-63. [Abstract] [Full-text]
80. Optimizing prostate cancer detection: 8 versus 12-core biopsy protocol.
    J Urol, 182(4): 1329-36. [Abstract] [Full-text]
81. Image guided photothermal focal therapy for localized prostate cancer: phase I trial.
    J Urol, 182(4): 1371-7. [Abstract] [Full-text]
82. Prostatic transition zone directed needle biopsies uncommonly sample clinically relevant transition zone tumors.
    J Urol, 182(4): 1337-41. [Abstract] [Full-text]
83. Cancer incidence among pesticide applicators exposed to butylate in the Agricultural Health Study (AHS).
    Environ Res, 109(7): 860-8. [Abstract] [Full-text]
84. Generation of an epigenetic signature by chronic hypoxia in prostate cells.
    Hum Mol Genet, 18(19): 3594-604. [Abstract] [Full-text]
85. Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3).
    Hum Mol Genet, 18(19): 3749-57. [Abstract] [Full-text]
86. Inhibitory mechanisms of Agaricus blazei Murill on the growth of prostate cancer in vitro and in vivo.
    J Nutr Biochem, 20(10): 753-64. [Abstract] [Full-text]
87. Effect of a prostaglandin--given rectally for prevention of radiation-induced acute proctitis--on late rectal toxicity. Results of a phase III randomized, placebo-controlled, double-blind study.
    Strahlenther Onkol, 185(9): 596-602. [Abstract] [Full-text]
88. Using cone-beam computed tomography to evaluate the impact of bladder filling status on target position in prostate radiotherapy.
    Strahlenther Onkol, 185(9): 588-95. [Abstract] [Full-text]
89. Outcomes of localized prostate cancer following conservative management.
    JAMA, 302(11): 1202-9. [Abstract] [Full-text]
90. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer.
    Cancer Res, 69(18): 7466-72. [Abstract] [Full-text]
91. Role of cyclic AMP response element-binding protein in insulin-like growth factor-i receptor up-regulation by sex steroids in prostate cancer cells.
    Cancer Res, 69(18): 7270-7. [Abstract] [Full-text]
92. Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
    Cancer Res, 69(18): 7366-74. [Abstract] [Full-text]
93. Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways.
    Cancer Res, 69(18): 7375-84. [Abstract] [Full-text]
94. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth.
    Cancer Res, 69(18): 7165-9. [Abstract] [Full-text]
95. Contemporary risk profile of prostate cancer in the United States.
    J Natl Cancer Inst, 101(18): 1280-3. [Abstract] [Full-text]
96. The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor.
    Cancer Res, 69(18): 7402-11. [Abstract] [Full-text]
97. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer.
    J Natl Cancer Inst, 101(18): 1272-9. [Abstract] [Full-text]
98. Case report. Multilocular cystadenoma of the prostate presenting as a giant pelvic mass.
    Br J Radiol, 82(982): e200-1. [Abstract] [Full-text]
99. The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer.
    Cancer Chemother Pharmacol, 65(1): 191-5. [Abstract] [Full-text]
100. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
     Oncogene, 28(37): 3307-19. [Abstract] [Full-text]
101. Early salvage radiotherapy for patients with PSA relapse after radical prostatectomy.
     J Cancer Res Clin Oncol, 135(11): 1561-7. [Abstract] [Full-text]
102. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.
     Cancer Chemother Pharmacol, 65(1): 177-86. [Abstract] [Full-text]
103. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
     Expert Rev Anticancer Ther, 9(9): 1211-8. [Abstract] [Full-text]
104. Towards the definition of prostate cancer-related microRNAs: where are we now?
     Trends Mol Med, 15(9): 381-90. [Abstract] [Full-text]
105. Characteristics of prostate cancers found in specimens removed by radical cystoprostatectomy for bladder cancer and their relationship with serum prostate-specific antigen level.
     Cancer Sci, 100(10): 1880-4. [Abstract] [Full-text]
106. Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model.
     Biochem Pharmacol, 78(9): 1127-38. [Abstract] [Full-text]
107. Association of lower urinary tract symptoms with sexual dysfunction: a cross-cultural study between Japanese and American men with localized prostate cancer.
     BJU Int, 104(8): 1071-6. [Abstract] [Full-text]
108. The prevalence of erectile dysfunction among Brazilian men screened for prostate cancer.
     BJU Int, 104(8): 1130-3. [Abstract] [Full-text]
109. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology.
     BJU Int, 104(8): 1091-7. [Abstract] [Full-text]
110. Retrospective analysis of the distance between the neurovascular bundle and prostate cancer foci in radical prostatectomy specimens: its clinical implication in nerve-sparing surgery.
     BJU Int, 104(8): 1085-90. [Abstract] [Full-text]
111. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure.
     BJU Int, 104(8): 1058-62. [Abstract] [Full-text]
112. Five-year longitudinal effect of radical perineal prostatectomy on health-related quality of life in Japanese men, using general and disease-specific measures.
     BJU Int, 104(8): 1077-84. [Abstract] [Full-text]
113. Intralesional recombinant alpha-interferon for localized prostate cancer: a pilot study with follow-up of >10 years.
     BJU Int, 104(8): 1068-70. [Abstract] [Full-text]
114. Prospective comparison of five mediators of the systemic response after high-intensity focused ultrasound and targeted cryoablation for localized prostate cancer.
     BJU Int, 104(8): 1063-7. [Abstract] [Full-text]
115. RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study.
     Radiat Oncol, 4: 34. [Abstract] [Full-text]
116. Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling.
     Oncogene, 28(38): 3390-400. [Abstract] [Full-text]
117. MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation.
     Oncogene, 28(38): 3360-70. [Abstract] [Full-text]
118. A luminal epithelial stem cell that is a cell of origin for prostate cancer.
     Nature, 461(7263): 495-500. [Abstract] [Full-text]
119. Polymorphisms of pro-inflammatory genes and prostate cancer risk: a pharmacogenomic approach.
     Cancer Immunol Immunother, 58(12): 1919-33. [Abstract] [Full-text]
120. Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation.
     Int J Cancer, 125(10): 2441-9. [Abstract] [Full-text]
121. Androgen receptor as a potential sign of prostate cancer metastasis.
     Prostate, 69(15): 1704-11. [Abstract] [Full-text]
122. Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats.
     Prostate, 69(15): 1668-82. [Abstract] [Full-text]
123. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+.
     Prostate, 69(15): 1694-703. [Abstract] [Full-text]
124. The lily-of-the-valley fragrance receptor--potential in prostate cancer imaging.
     Prostate, 69(15): 1599-602. [Abstract] [Full-text]
125. In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue.
     Prostate, 69(15): 1683-93. [Abstract] [Full-text]
126. Comparison of ACINUS, caspase-3, and TUNEL as apoptotic markers in determination of tumor growth rates of clinically localized prostate cancer using image analysis.
     Prostate, 69(15): 1603-10. [Abstract] [Full-text]
127. A novel androgen-dependent prostate cancer xenograft model derived from skin metastasis of a Japanese patient.
     Prostate, 69(15): 1660-7. [Abstract] [Full-text]
128. Correlation between selenium concentrations and glutathione peroxidase activity in serum and human prostate tissue.
     Prostate, 69(15): 1635-42. [Abstract] [Full-text]
129. Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines.
     Int J Cancer, 125(10): 2288-95. [Abstract] [Full-text]
130. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.
     Prostate, 69(15): 1624-34. [Abstract] [Full-text]
131. A novel model of bone-metastatic prostate cancer in immunocompetent mice.
     Prostate, 69(15): 1613-23. [Abstract] [Full-text]
132. Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment.
     Cancer Lett, 285(1): 58-65. [Abstract] [Full-text]
133. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study).
     Arch Intern Med, 169(17): 1611-8. [Abstract] [Full-text]
134. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
     Arch Intern Med, 169(17): 1603-10. [Abstract] [Full-text]
135. Identification of a new prostate cancer susceptibility locus on chromosome 8q24.
     Nat Genet, 41(10): 1055-7. [Abstract] [Full-text]
136. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility.
     Nat Genet, 41(10): 1122-6. [Abstract] [Full-text]
137. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study.
     Nat Genet, 41(10): 1116-21. [Abstract] [Full-text]
138. Multiple loci on 8q24 associated with prostate cancer susceptibility.
     Nat Genet, 41(10): 1058-60. [Abstract] [Full-text]
139. A comparative study of recombinant and native frutalin binding to human prostate tissues.
     BMC Biotechnol, 9: 78. [Abstract] [Full-text]
140. Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement.
     Br J Cancer, 101(7): 1137-44. [Abstract] [Full-text]
141. Peripheral zone prostate cancer in patients with elevated PSA levels and low free-to-total PSA ratio: detection with MR imaging and MR spectroscopy.
     Radiology, 253(1): 135-43. [Abstract] [Full-text]
142. Treatment of prostate cancer in unfit senior adult patients.
     Cancer Treat Rev, 35(6): 522-7. [Abstract] [Full-text]

© 2004-2012 Prostate Cancer Research Today. All Rights Reserved.